Proteomic analysis of porcine corpus luteum during the estrous cycle: effects of PPAR gamma ligans

Poster.-- 28th Congress of the Polish Physiological Society, September 15–17, 2021, (Online), Gdansk, Poland

The corpus luteum (CL) is an endocrine gland present in the ovary of mature females during the estrous cycle as well as pregnancy. There is evidence indicating the relationship between secretory function of the CL and peroxisome proliferator-activated receptors (PPARs). In this study, we investigate the impact of PPARg ligands on the proteomic profile of the CL during the mid-luteal phase (days 10–12) and late-luteal phase (days 14–16) of the estrous cycle. The CL slices were incubated in vitro for 6 h in the presence of PPARg ligands (agonist pioglitazone, antagonist T0070907) or without ligands (control; n=4 for each group). Global proteomic analysis was performed by TMT-based LC MS/MS method. We identified in total 586 proteins in the pig’s corpus luteum. Comparative proteomics analysis indicated that 7 various proteins were differentially regulated (DRPs, significantly confirmed by Kruskal-Wallis one-way analysis of variance, adjusted p-value <0.05) in the CL tissue treated with PPAR ligands. In the mid-luteal phase one protein, CAND1, was downregulated after T0070907 treatment. In the group of the upregulated DRPs in the late-luteal phase of the CL treated with pioglitazone we identified: SPTAN1, GOLGB1, TP53BP1, MATR3, RRBP1 and SRRT. Three of them - SPTAN1, GOLGB1 and TP53BP1, were also upregulated in the CL in the late-luteal phase treated with T0070907. Interestingly, CAND1 and RRBP1 are a potential prognostic biomarkers in various types of cancers, due to their involvement in tumor formation and progression. Moreover, the mid-luteal phase control vs. late-luteal phase control comparison analysis showed that certain proteins constitute a specific proteomic signature for each of the examined phases, i.e., 23 and 28 proteins for the mid-and late-luteal phase, respectively. These results provide a basis for further research on the influence of PPARg ligands on the expression of tumor biomarkers

Supported by National Science Centre, Poland, grant no. 2017/27/N/NZ9/00907

No